(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/255408 A1

(51) International Patent Classification:
*C07D 487/04* (2006.01) *A61P 37/00* (2006.01)
*A61P 17/00* (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/JP2022/022306

(22) International Filing Date:
01 June 2022 (01.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2021-092947 02 June 2021 (02.06.2021) JP

(71) Applicant: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors: **UEMATSU, Yukitaka**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **OKADA, Minoru**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **SAITO, Akihiro**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **TAKAHASHI, Akira**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **NAKAMURA, Yuichi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **HANARI, Taiki**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **MENJO, Yasuhiro**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **YAMAUCHI, Takahito**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **YAMAGUCHI, Atsushi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **YUKI, Yohei**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **WATANABE, Kenji**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). **MATSUDA, Satoshi**; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP).

(74) Agent: **YAMAO, Norihito** et al.; AOYAMA & PARTNERS, Osaka Umeda Twin Towers North, 8-1, Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*

WO 2022/255408 A1

(54) Title: PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS



[I]

(57) Abstract: Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]: wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.